Unknown PHASE1 INTERVENTIONAL 1-arm NCT03507998

Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors

A Phase 1 Open-label Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors

Sponsor: Curegenix Inc.

Conditions Bile Duct Carcinoma Colorectal Adenocarcinoma Esophageal Carcinoma Gastric Adenocarcinoma Gastrointestinal Cancer Hepatocellular Carcinoma Pancreatic Adenocarcinoma

Interventions CGX1321

Updated 8 times since 2018 Last updated: Jul 22, 2020 Started: Jun 17, 2017 Primary completion: Apr 1, 2021 Completion: Apr 1, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03507998, this PHASE1 trial focuses on Bile Duct Carcinoma and Colorectal Adenocarcinoma and remains ongoing. Sponsored by Curegenix Inc., it has been updated 8 times since 2017, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Sep 2022 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Jan 2021 — Sep 2022 [monthly]

Recruiting PHASE1
Aug 2020 — Jan 2021 [monthly]

Recruiting PHASE1

▶ Show 3 earlier versions

Jun 2019 — Aug 2020 [monthly]

Recruiting PHASE1
Apr 2019 — Jun 2019 [monthly]

Recruiting PHASE1
May 2018 — Apr 2019 [monthly]

Recruiting PHASE1

First recorded

Jun 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Curegenix Inc.
Guangzhou Curegenix Co. Ltd.

Data source: Curegenix Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China